HF-125, a first-in-class computer-modeled novel inhibitor of Tribbles 2, for therapy of enzalutamide resistant, neuroendocrine prostate cancer.
Sougata Ghosh Chowdhury, Pritam Biswas, Jitender Monga, Steve Brown, Craig Rogers, Jagadananda Ghosh
This paper designs HF-125, a TRIB2 inhibitor, using AI-based modeling to treat enzalutamide-resistant neuroendocrine prostate cancer.
bioRxiv · Apr 30, 2026 · PreprintCancer Biology